Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESPB vs PVPB for PMPS Prevention in Breast Cancer Surgery
NCT06036979Not yet recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of bupivacaine hydrochloride 0.75% injection in Post-mastectomy pain syndrome (PMPS) (3 arms), sponsored by National Cancer Institute. Primary endpoint: Incidence of Post-Mastectomy Pain Syndrome at 3 months. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
bupivacaine hydrochloride 0.75% injection
03
Conditions
Post-mastectomy pain syndrome (PMPS)
Beyond the preview
Go deeper on NCT06036979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06036979.